我国已上市的PEG-rhG-CSF不仅包括培非格司亭的生物类似物，还包括具有创新结构的Y型PEG-rhG-CSF——拓培非格司亭。拓培非格司亭的创新点在于其PEG修饰分子是Y型支链结构，且分子中含有更多的环氧乙烷单元，分子量为40 kD，是传统线型PEG的2倍。
这些创新落实到临床上来，能够给患者带来什么？今天，就让我们一起来看看拓培非格司亭的Ⅲ期研究中，给NSCLC治疗带来了哪些改变吧！
1. ESMO Asia Congress 2023. Xinshuai Wang, et al. 441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study. Annals of Oncology (2023) 34 (suppl_4): S1632-S1645.
2. 拓培非格司亭注射液说明书
3. Sci Rep. 2024;14(1):3816.
4. Support Care Cancer. 2022;30(9):7067-7077.
5. Front Oncol. 2023;12:1026377.
6. Cancers (Basel). 2023;15(14):3675.
7. JAMA Netw Open. 2021;4(11):e2133474.
8. BioDrugs. 2019;33(6):621-634.
9. G-CSF(Granulocyte Colony Stimulating Factors)Global Market Report 2023
10. G-CSF(Granulocyte Colony Stimulating Factors)Global Market Report 2024
